Profile data is unavailable for this security.
About the company
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
- Revenue in USD (TTM)423.00k
- Net income in USD-28.50m
- Incorporated2011
- Employees10.00
- LocationVyne Therapeutics Inc685 Route 202/206 N., Suite 301BRIDGEWATER 08807United StatesUSA
- Phone+1 (650) 486-1416
- Fax+1 (302) 655-5049
- Websitehttps://vynetherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marker Therapeutics Inc | 3.32m | -12.21m | 34.52m | 8.00 | -- | 2.92 | -- | 10.39 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 34.93m | 6.00 | -- | 453.00 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 35.50m | 163.00 | -- | 0.174 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 35.51m | 55.00 | -- | 1.19 | -- | 2.10 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Surrozen Inc | 0.00 | -37.58m | 35.86m | 42.00 | -- | 0.7838 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -30.28m | 35.87m | 32.00 | -- | 0.4836 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Janone Inc | 0.00 | -18.58m | 35.95m | 5.00 | -- | -- | -- | -- | -3.66 | -3.95 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -69.38 | -23.12 | -88.46 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.1264 | -- | -- | -- | -313.15 | -- | -- | -- |
| OncoCyte Corp | 1.38m | -40.66m | 36.62m | 43.00 | -- | 1.96 | -- | 26.50 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Cyclo Therapeutics Inc | 1.13m | -19.39m | 36.63m | 8.00 | -- | 60.04 | -- | 32.52 | -1.03 | -1.03 | 0.0557 | 0.0213 | 0.2001 | 0.4155 | 11.12 | 140,806.30 | -344.43 | -132.22 | -17,225.46 | -215.17 | 91.02 | 90.37 | -1,721.63 | -1,114.04 | 0.968 | -- | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Fortress Biotech Inc | 85.11m | -62.86m | 36.65m | 186.00 | -- | 1.55 | -- | 0.4306 | -6.65 | -6.65 | 7.96 | 1.19 | 0.3976 | 2.27 | 4.55 | 457,602.20 | -64.47 | -52.50 | -107.85 | -99.46 | 68.25 | 63.17 | -162.17 | -236.94 | 1.21 | -10.18 | 1.07 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Vyne Therapeutics Inc | 423.00k | -28.50m | 36.90m | 10.00 | -- | 0.4357 | -- | 87.24 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Lipocine Inc | 4.71m | -8.97m | 37.01m | 17.00 | -- | 1.54 | -- | 7.86 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Movano Inc | 852.00k | -27.91m | 37.71m | 30.00 | -- | -- | -- | 44.27 | -0.5593 | -0.5593 | 0.0168 | -0.0263 | 0.0779 | -- | 2.12 | 28,400.00 | -254.99 | -151.50 | -559.26 | -188.58 | -42.61 | -- | -3,275.47 | -- | 0.5147 | -- | -- | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Mink Therapeutics Inc | 0.00 | -20.59m | 38.19m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
Data as of May 30 2024. Currency figures normalised to Vyne Therapeutics Inc's reporting currency: US Dollar USD
51.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 31 Mar 2024 | 1.39m | 9.89% |
| Eventide Asset Management LLCas of 31 Mar 2024 | 1.39m | 9.89% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.18m | 8.38% |
| Parkman Healthcare Partners LLCas of 31 Mar 2024 | 696.47k | 4.94% |
| DSC Advisors LPas of 31 Mar 2024 | 696.47k | 4.94% |
| LifeSci Fund Management LLCas of 31 Dec 2023 | 668.15k | 4.74% |
| Palo Alto Investors LPas of 31 Mar 2024 | 445.43k | 3.16% |
| Exome Asset Management LLCas of 31 Mar 2024 | 415.43k | 2.95% |
| Schonfeld Strategic Advisors LLCas of 31 Mar 2024 | 219.80k | 1.56% |
| RBC Capital Markets LLC (Investment Management)as of 31 Mar 2024 | 173.00k | 1.23% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
